Home > Newsletters > FDAnews Drug Daily Bulletin > UK May Allow Early Access to Drugs Based on Strong Phase II, III Trials
FDAnews Drug Daily Bulletin
Aug. 27, 2012 | Vol. 9 No. 168
UK May Allow Early Access to Drugs Based on Strong Phase II, III Trials
Strong Phase III or even Phase II data may enable drugmakers to sell certain medicines for unmet needs in the UK before they are approved, thanks to a developing early access program. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is proposing the scheme, which would provide access to promising new drugs about a year before they are brought to market.
Clinical Trials Advisor
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.